Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Melanoma × canakinumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 5 Triple Negative Breast Neoplasms 1 Rheumatoid Arthritis, Systemic Juvenile 1 Rectal Neoplasms 1 Periodic Fevers Syndrome 1 Neoplasms 1 Neoplasm Metastasis 1 Mevalonate Kinase Deficiency 1 Melanoma 1 Lung Neoplasms 1 Intestinal Neoplasms 1 Cryopyrin-Associated Periodic Syndromes 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Ductal 1 Carcinoma 1 Bronchiolitis Obliterans Syndrome 1 Breast Neoplasms 1 Arthritis, Juvenile 1 Arthralgia 1 Adenocarcinoma of Lung 1 Adenocarcinoma 1

Interventions

pembrolizumab 146 Nivolumab 98 Ipilimumab 82 Dacarbazine 40 trametinib 34 dabrafenib 30 Vemurafenib 28 atezolizumab 21 binimetinib 19 Temozolomide 19 cemiplimab 16 Paclitaxel 15 cobimetinib 14 spartalizumab 13 encorafenib 12 Cisplatin 12 Carboplatin 12 Cyclophosphamide 10 talimogene laherparepvec 9 lenvatinib 9 durvalumab 9 Docetaxel 9 tremelimumab 8 relatlimab 8 Gemcitabine 8 Drug Therapy 8 Bevacizumab 8 Pemetrexed 7 Albumin-Bound Paclitaxel 7 130-nm albumin-bound paclitaxel 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03484923 2024-06-18

PLATforM

Novartis

Phase 2 Completed

196 enrolled 22 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡